Switch theme
Sign up to access all valuation multiples
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
2012
166
LTM Revenue $24.8M
LTM EBITDA -$23.5M
-$26.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ProQR Therapeutics has a last 12-month revenue of $24.8M and a last 12-month EBITDA of -$23.5M.
In the most recent fiscal year, ProQR Therapeutics achieved revenue of $18.9M and an EBITDA of -$24.1M.
ProQR Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ProQR Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.5M | $18.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$24.1M | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | -370% | -128% | XXX | XXX | XXX |
| Net Profit | -$65.1M | -$28.1M | XXX | XXX | XXX |
| Net Margin | -1000% | -149% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ProQR Therapeutics's stock price is $1.
ProQR Therapeutics has current market cap of $124M, and EV of -$26.0M.
See ProQR Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$26.0M | $124M | XXX | XXX | XXX | XXX | $-0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ProQR Therapeutics has market cap of $124M and EV of -$26.0M.
ProQR Therapeutics's trades at -1.1x LTM EV/Revenue multiple, and 1.2x LTM EBITDA.
Analysts estimate ProQR Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ProQR Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$26.0M | XXX | XXX | XXX |
| EV/Revenue | -1.4x | XXX | XXX | XXX |
| EV/EBITDA | 1.1x | XXX | XXX | XXX |
| P/E | -4.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpProQR Therapeutics's NTM/LTM revenue growth is 20%
ProQR Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, ProQR Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ProQR Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ProQR Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 190% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -128% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -108% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 72% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 192% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 261% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ProQR Therapeutics acquired XXX companies to date.
Last acquisition by ProQR Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . ProQR Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ProQR Therapeutics founded? | ProQR Therapeutics was founded in 2012. |
| Where is ProQR Therapeutics headquartered? | ProQR Therapeutics is headquartered in United States of America. |
| How many employees does ProQR Therapeutics have? | As of today, ProQR Therapeutics has 166 employees. |
| Who is the CEO of ProQR Therapeutics? | ProQR Therapeutics's CEO is Mr. Daniel de Boer. |
| Is ProQR Therapeutics publicy listed? | Yes, ProQR Therapeutics is a public company listed on NAS. |
| What is the stock symbol of ProQR Therapeutics? | ProQR Therapeutics trades under PRQR ticker. |
| When did ProQR Therapeutics go public? | ProQR Therapeutics went public in 2014. |
| Who are competitors of ProQR Therapeutics? | Similar companies to ProQR Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ProQR Therapeutics? | ProQR Therapeutics's current market cap is $124M |
| What is the current revenue of ProQR Therapeutics? | ProQR Therapeutics's last 12-month revenue is $24.8M. |
| What is the current EBITDA of ProQR Therapeutics? | ProQR Therapeutics's last 12-month EBITDA is -$23.5M. |
| What is the current EV/Revenue multiple of ProQR Therapeutics? | Current revenue multiple of ProQR Therapeutics is -1.1x. |
| What is the current EV/EBITDA multiple of ProQR Therapeutics? | Current EBITDA multiple of ProQR Therapeutics is 1.2x. |
| What is the current revenue growth of ProQR Therapeutics? | ProQR Therapeutics revenue growth between 2023 and 2024 was 190%. |
| Is ProQR Therapeutics profitable? | Yes, ProQR Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
